Journal
STEM CELLS
Volume 26, Issue 11, Pages 2753-2758Publisher
WILEY
DOI: 10.1634/stemcells.2008-0421
Keywords
Induced pluripotent stem cells; Embryonic stem cell; Somatic cell nuclear transfer; Pluripotency; Reprogramming
Categories
Funding
- Craig H. Neilsen Foundation
- NIH [R01-NS048382]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048382] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The development of personalized pluripotent stem cells for research and for possible therapies holds out great hope for patients. However, such cells will face significant technical and regulatory challenges before they can be used as therapeutic reagents. Here we consider two possible sources of personalized pluripotent stem cells: embryonic stem cells derived from nuclear transfer (NT-ESCs) and induced pluripotent stem cells (iPSCs) derived from direct reprogramming of adult somatic cells. Both sources of personalized pluripotent stem cells face unique regulatory hurdles that are in some ways significantly higher than those facing stem cells derived from embryos produced by fertilization (ESCs). However, the outstanding long-term potential of iPSCs and their relative freedom from the ethical concerns raised by both ESCs and NT-ESCs makes direct reprogramming an exceptionally promising approach to advancing research and providing therapies in the field of regenerative medicine. STEM CELLS 2008;26:2753-2758
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available